DA32 Life Science Tech Acquisition Corp. is a blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has assembled a seasoned executive team, board of directors and strategic advisors who individually and collectively bring experience in investing, scaling and commercializing important life sciences tools, diagnostics, and data and analytics platforms to improve human health. While the Company may pursue a business combination target in any business or industry, the Company intends to capitalize on the complementary strengths and operating experience of its management team, board and advisors to identify promising opportunities in the life science technology sector.
Company profile
Ticker
DALS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
863352988
DALS stock data
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
8-K
Report of Independent Registered Public Accounting Firm
5 Aug 21
8-K
Entry into a Material Definitive Agreement
30 Jul 21
424B4
Prospectus supplement with pricing info
29 Jul 21
EFFECT
Notice of effectiveness
28 Jul 21
CERT
Certification of approval for exchange listing
27 Jul 21
Latest ownership filings
SC 13G/A
Wellington Management Portfolios (Dublin) Public Ltd Co
6 Feb 23
SC 13G/A
VICTORY CAPITAL MANAGEMENT INC
6 Feb 23
SC 13G/A
BlackRock Inc.
31 Jan 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
10 Feb 22
SC 13G
Saba Capital Management, L.P.
7 Feb 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
4 Feb 22
SC 13G/A
Wellington Management Portfolios (Dublin) Public Ltd Co
4 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22
SC 13G
VICTORY CAPITAL MANAGEMENT INC
2 Feb 22
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
10 Aug 21
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 861.24 k | 861.24 k | 861.24 k | 861.24 k | 861.24 k | 861.24 k |
| Cash burn (monthly) | 79.93 k | 90.94 k | (no burn) | 53.38 k | 335.08 k | 118.75 k |
| Cash used (since last report) | 343.56 k | 390.86 k | n/a | 229.45 k | 1.44 mm | 510.41 k |
| Cash remaining | 517.67 k | 470.38 k | n/a | 631.78 k | -579.00 k | 350.82 k |
| Runway (months of cash) | 6.5 | 5.2 | n/a | 11.8 | -1.7 | 3.0 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 47 |
| Opened positions | 4 |
| Closed positions | 6 |
| Increased positions | 5 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 343.93 mm |
| Total shares | 34.85 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| ARCH Venture Fund XI | 6.72 mm | $67.15 mm |
| Section 32 Fund 3 | 6.12 mm | $61.15 mm |
| DA32 Sponsor | 5.12 mm | $51.15 mm |
| Deerfield Management | 1.60 mm | $15.57 mm |
| BLK Blackrock | 1.50 mm | $14.60 mm |
| Ra Capital Management | 1.50 mm | $14.60 mm |
| Wellington Management Portfolios | 1.48 mm | $14.51 mm |
| Saba Capital Management | 1.26 mm | $12.24 mm |
| Magnetar Financial | 936.00 k | $9.11 mm |
| Marshall Wace | 896.94 k | $8.73 mm |